Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy

Journal of Experimental Medicine

Volumn 194, Issue 4, 2001, Pages 481-489

  Van Elsas, A ^a   Sutmuller, R P M ^a   Hurwitz, A A ^a   Ziskin, J ^a   Villasenor, J ^a   Medema, J P ^a   Overwijk, W W ^a   Restifo, N P ^a   Melief, C J M ^a   Offringa, R ^a   Allison, J P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Depigmentation; Immunotherapy; Prophylaxis; T lymphocyte; TRP 2

Indexed keywords

CELL ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS ANTIGEN; FAS LIGAND; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; MELANOCYTE ANTIGEN; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE; PERFORIN; TYROSINASE RELATED PROTEIN 1; TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CANCER THERAPY; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEPIGMENTATION; DRUG TARGETING; FEMALE; IMMUNOTHERAPY; INTERMETHOD COMPARISON; MELANOCYTE; MOUSE; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROPHYLAXIS; TUMOR REJECTION;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; B-LYMPHOCYTES; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNOCONJUGATES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL;

EID: 17944364189     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.194.4.481     Document Type: Article

References (40)

1. Design and evaluation of antigen-specific vaccination strategies against cancer
2. + T cell responses in antitumor inmmunity
3. Sequential chemoimmunotherapy in the treatment of metastatic melanoma
4. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy
5. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo
6. Melanocyte destruction after antigen-specific immunotherapy of melanoma. Direct evidence of T cell-mediated vitiligo
7. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy
8. Enhancement of antitumor immunity by CTLA-4 blockade
9. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
10. CTLA-4 blockade synergizes with tumor-derived GM-CSF for treatment of an experimental mammary carcinoma
11. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice
12. Elimination of residual metastatic prostate cancer following surgery and adjunctive CTLA-4 blockade immunotherapy
13. Combination immunotherapy of B16 melanoma using anti-CTLA-4 and GM-CSF producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
14. Combination immunotherapy of primary prostate cancer in a transgenic model using CTLA-4 blockade
15. Vaccination with irradiated tumor cells engineered to secrete GM-CSF stimulates potent, specific, and long lasting anti-tumor immunity
16. + T cells in the antitumor immune response
17. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
18. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules
19. gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
20. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells
21. Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the brown locus protein
22. B cells inhibit induction of T cell-dependent tumor immunity
23. Immune escape of tumors in vivo by expression of cellular FLICE- inhibitory protein
24. Decreased tumor surveillance in perforin-deficient mice
25. Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice
26. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
27. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model
28. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive CTL responses
29. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
30. Coupling and uncoupling of tumor immunity and autoimmunity
31. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: Evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2)
32. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy
33. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
34. Help for cytotoxic-T-cell responses is mediated by CD40 signaling
35. + T-helper and a T-killer cell
36. + T cell help
37. Fas and Fas ligand interactions suppress melanoma lung metastasis
38. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors
39. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo
40. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains